Celebrations may be in order for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. Investors have been pretty optimistic on NewAmsterdam Pharma too, with the stock up 30% to US$38.89 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.

After this upgrade, NewAmsterdam Pharma's 14 analysts are now forecasting revenues of US$29m in 2026. This would be a substantial 29% improvement in sales compared to the last 12 months. Losses are forecast to hold steady at around US$1.82 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$25m and losses of US$1.94 per share in 2026. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

There was no major change to the consensus price target of €42.94, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values NewAmsterdam Pharma at €50.92 per share, while the most bearish prices it at €32.28. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting NewAmsterdam Pharma's growth to accelerate, with the forecast 41% annualised growth to the end of 2026 ranking favourably alongside historical growth of 12% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that NewAmsterdam Pharma is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around NewAmsterdam Pharma's prospects. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at NewAmsterdam Pharma.

That's a pretty serious upgrade, but shareholders might be even more pleased to know that forecasts expect NewAmsterdam Pharma to be able to reach break-even within the next few years. You can learn more about these forecasts, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.